Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZSP1241 in Advanced Solid Tumors
NCT03734926Phase 1Unknown
- Sponsor
- Zhongsheng Pharma
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ZSP1241 in hepatocellular carcinoma (HCC), cholangiocarcinoma (CCA), gastric cancer (GC) and 3 more (3 arms), sponsored by Zhongsheng Pharma. Primary endpoints: Maximum Tolerated Dose at Day 28, Dose Limiting Toxicity at Day 28 and 1 more. Status: unknown.
02
Drugs
ZSP1241
03
Conditions
hepatocellular carcinoma (HCC)cholangiocarcinoma (CCA)gastric cancer (GC)esophageal cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03734926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03734926.